<DOC>
	<DOC>NCT00002084</DOC>
	<brief_summary>To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or &gt; 100 cells/mm3.</brief_summary>
	<brief_title>A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpesviridae Infections</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection with CD4 counts = or &gt; 100 cells/mm3. Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years. History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study. Exclusion Criteria Coexisting Condition: Patients with the following symptoms and conditions are excluded: Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy. Concurrent Medication: Excluded: Systemic antiherpes medication. Interferon. Patients with the following prior conditions are excluded: History of hypersensitivity to acyclovir.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Acyclovir</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anus Diseases</keyword>
	<keyword>Herpes Genitalis</keyword>
</DOC>